For clinical trial of
Medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt®), on viral
loads and CD4-lymphocytes counts of HIV/AIDS patients, 10 volunteers were
treated. Their blood samples were tested for viral loads and for
CD4-lymphocytes counts, before the treatment and every 4 weeks during the
medication. The regimen was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin
trihydrate (7.5 mg/kg) and immunace extra protection® (1 tablet/day), for 4
weeks. Then, it was reduced to 50 mg/kg (MSAMS) and the immune stimulant. When
their viral loads become undetectable, they would be treated for additional 4
weeks. Initially, the Antivirt®-regimen appeared to worsen both HIV
infection-load and immune deficiency but later relieved them. Patients’ mean-viral
load increased (P = 0.020), from 1820.30 ± 868.75 to 2855.90 ± 960.98, after 4
weeks before reducing (P = 0.030) to 1565.20 ± 743.17, after 8 weeks.
Similarly, their mean-CD4-lymphocytes count reduced (P = 0.008) from 496.80 ±
194.39 to 263.90 ± 149.26, after 4 weeks before improving (P = 0.001) to 507.90
± 133.19, after 8 weeks.
Cristina, E., Ivan, P. and Kevin, R. (2007) Nanomaterials and Nanoparticles: Sources and Toxicity. Biointerphases, 2, 17-21.
[3]
Yokoyama, M. (2011) Structural Mechanisms of Immune Evasion of HIV 1 gp 120 by Genomic Computational and Experimental Science. Uirusu, 61, 49-57. http://dx.doi.org/10.2222/jsv.61.49
[4]
Dennis, V.P. and Lasse, K. (2013) Students Discover Method to Kill Cancer. M.Sc. thesis, University of Engineering Finland.
[5]
Brooks, G.F. (1998) Medical Microbiology. 21st Edition, Mc Graw Hill Education Inc., San Franscisco.
[6]
Ezeibe, M.C.O. and Ogbonna, I.J. (2015) Acquired Immune Deficiency Syndrome in Man and Animals—A Review. World Journal of AIDS, 5, 50-57.
[7]
World Health Organization (2007) Laboratory Guidelines for Enumerating CD4 T Lymphocytes in the Context of HIV/AIDS. World Health Organization Regional Office for South-East Asia, New Delhi.
[8]
Galindo, L.A. and Cereso, P. (2006) Compositional, Technical and Safety Specification of Clay to Be Used as Pharmaceutical and Cosmetic Products. Journal of Renal Nutrition, 2, 38-40.
[9]
Ezeibe, M.C.O. (2014) The Medicinal Synthetic Aluminum-Magnesium Silicate (Nanoparticles)—Antiviral Agent and Adjuvant to Chemotherapeutics. Federal Republic of Nigeria Patents and Designs Ref No.: NG/P/2012/639.
[10]
Murray, K.R. (2000) Harpers Biochemistry. McGraw Hill, New York.
[11]
Ezeibe, M.C.O., Ngene, A.A., Kalu, I.K., Ezeh, I.O., Mbuko, I.J., Ekwuruke, J.O., Anene, I., Amechi, B., Olowoniyi, P. and Ifekwe, I.F. (2014) Assessment of Antiretroviral Effects of a Synthetic Aluminum-Magnesium Silicate. BJMMR, 4, 1672-1679.
[12]
Ezeibe, M.C.O., Ijabo, O., Uzopuo, C., Okoroafor, O.N., Eze, J.I. Mbuko, I.J., Sanda, M.E., Animoke, P.C. and Ngene, A.A. (2011) Effects of Aluminium-Magnesium Silicate on Newcastle Disease Virus and on Recovery of Infected Chicks. International Journal of Biological and Chemical Sciences, 5, 825-829.
http://dx.doi.org/10.4314/ijbcs.v5i2.72160
[13]
Ezeibe, M.C.O., Mbuko, I.J., Okoroafor, O.N., Okonkwo, A.C., Animoke, P.C., Orajaka, L.J.E. and Ngene, A.A. (2009) In Vitro and in Vivo Effects of Aluminum-Magnesium Silicate on Infectious Bursal Disease Virus in Chiken. Animal Science Reporter, 3, 132-137.
Ezeibe, M.C.O. and Ogbonna, I.J. (2015) Medicinal Synthetic Aluminum-Magnesium Silicate. Al4(SiO4)3 + 3Mg2SiO4 → 2Al2Mg3(SiO4)3: A Highly Active Anti-Retroviral Medicine. Journal of Antivirals & Antiretrovirals, 7, 98.
[16]
Ezeibe, M.C.O. and Ogbonna, I.J. (2015) Enhancing Efficacy of Antimicrobials with the Medicinal Synthetic Aluminum-Magnesium Silicate, for Prevention and Treatment of Resistant Infections. BJMMR, 9, 1-8.
http://dx.doi.org/10.9734/BJMMR/2015/17768
[17]
Ezeibe, M.C.O. and Ogbonna, I.J. (2015) Synergy between Effects of the Medicinal Synthetic Aluminum-Magnesium Silicate and B-Vitamins, on Anti-Plasmodial Activities of Chloroquine. BJMMR. (In Print).
